登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，2月27日，COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-02-28

  • COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia

    Shahul H Ebrahim

    Ziad A Memish

    Published:February 27, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30466-9

    The ongoing coronavirus disease 2019 (COVID-19) outbreak is a Public Health Emergency of International Concern (PHEIC), and the emergence of new epicentres of spread, such as South Korea and Iran, besides Wuhan, China, should draw attention to potential superspreader events.1 Of concern is the continuous Umrah pilgrimage to Saudi Arabia by Muslim pilgrims from more than 180 countries. In addition to the non-pilgrim air traffic (39 million people in 2018), Saudi Arabia received 7·5 million Umrah visa holders in 2019 (appendix).

  • 原文来源：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30466-9/fulltext
88浏览量
原文链接
相关报告

  • 《LANCET，2月27日，Convalescent plasma as a potential therapy for COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • Convalescent plasma as a potential therapy for COVID-19 Long Chen, Jing Xiong, Lei Bao, Yuan Shi Published:February 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30141-9 The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). By Feb 22, 2020, this virus has affected more than 77?700 people worldwide and caused more than 2300 deaths. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged.1 However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.
    88浏览量
    原文链接

  • 《LANCET，2月27日，Looming threat of COVID-19 infection in Africa: act collectively, and fast》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • Looming threat of COVID-19 infection in Africa: act collectively, and fast John N Nkengasong, Wessam Mankoula Published:February 27, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30464-5 Because of the high volume of air traffic and trade between China and Africa,1 Africa is at a high risk for the introduction and spread of the novel coronavirus disease 2019 (COVID-19); although only Egypt has reported the first case, from a non-national.2 The greatest concern for public health experts is whether COVID-19 will become a pandemic, with sustained year-round transmission, similar to influenza, as is now being observed in several countries.3 What might happen to Africa—where most countries have weak health-care systems, including inadequate surveillance and laboratory capacity, scarcity of public health human resources, and limited financial means—if a pandemic occurs? With neither treatment nor vaccines, and without pre-existing immunity, the effect might be devastating because of the multiple health challenges the continent already faces: rapid population growth and increased movement of people; existing endemic diseases, such as human immunodeficiency virus, tuberculosis, and malaria; remerging and emerging infectious pathogens such as Ebola virus disease, Lassa haemorrhagic fever, and others; and increasing incidence of non-communicable diseases.
    157浏览量
    原文链接